EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tescalcin is a phagocytic checkpoint driving immune escape and limiting immunotherapeutic efficacy in hepatocellular carcinoma

Jiong-Liang Wang, Jun-Cheng Wang, Yangxun Pan, Minrui He, Zhikai Zheng, Hao Zou, Tianqing Wu, Yuhan Zhang, Zili Hu, Yizhen Fu, Wei Peng, Zhenyun Yang und 8 weitere

Journal of Clinical Investigation · 01.06.2026 · 136 (11)

DOI: 10.1172/jci200415 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 02.04.2026. Verfasst von Jiong-Liang Wang und 19 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Department of Liver Surgery, Sun Yat-sen Uni…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Tumor Escape, Phagocytosis. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province, China, Beijing Kechuang Medical Development Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapies achieve durable responses in several cancers but show limited efficacy in refractory hepatocellular carcinoma (HCC). The mechanisms by which hepatoma cells evade immune recognition and limit immune checkpoint blockade (ICB) efficacy are incompletely defined. Here, we identified tumor-intrinsic tescalcin (TESC) as a previously unrecognized phagocytic checkpoint that contributes to immune evasion and ICB resistance in HCC. Mechanistically, H3K4 methylation drove TESC expression in hepatoma cells, facilitating cytosolic Ca 2+ buffering and attenuating endoplasmic reticulum (ER) stress–induced calreticulin (CALR) plasma membrane exposure, an essential “eat-me” signal. Consequently, this process abrogated membrane CALR-directed phagocytosis by antigen-presenting cells (APCs), including macrophages and DCs, thereby impairing antigen presentation and subsequent T cell activation. Clinically, we found that elevated H3K4me3-TESC signaling was a promising prognostic biomarker for a poor ICB response in HCC. Importantly, in vivo disruption of this axis restored APC phagocytic function and enhanced the antitumor effects of ICB therapy. Therefore, targeting TESC-driven immune escape and its underlying epigenetic regulation may restore APC function and offer a precise therapeutic strategy to enhance immunotherapeutic efficacy in HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsTumor EscapePhagocytosisNeoplasm ProteinsImmunotherapyCalcium-Binding ProteinsHumansAnimalsMiceCalreticulinCell Line, Tumor

Stichwörter der Autor:innen

Cancer immunotherapyHepatologyImmunologyLiver cancerMacrophagesOncology

Substanzen

Neoplasm ProteinsCalreticulinCalcium-Binding Proteins

Autor:innen und Institutionen

  • State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Guangdong Province Key Laboratory of Pharmaceutical Functional Genes, MOE Key Laboratory of Gene Function and Regulation, School of Life Sciences, Sun Yat-sen University, Guangzhou, China.
  • State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Department Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Department of Radiation Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Guangdong Province, China
  • Beijing Kechuang Medical Development Foundation
  • Beijing Weiai Public Welfare Foundation

Zitieren

APA

Wang, J. L., Wang, J. C., Pan, Y., He, M., Zheng, Z., Zou, H., Wu, T., Zhang, Y., Hu, Z., Fu, Y., Peng, W., Yang, Z., Xu, L., Zhang, Y. J., Chen, M. S., Hu, D., Chen, J., Zhao, M., Chen, D. P., & Zhou, Z. G. (2026). Tescalcin is a phagocytic checkpoint driving immune escape and limiting immunotherapeutic efficacy in hepatocellular carcinoma. Journal of Clinical Investigation, 136(11). https://doi.org/10.1172/jci200415

Vancouver

Wang JL, Wang JC, Pan Y, He M, Zheng Z, Zou H, et al. Tescalcin is a phagocytic checkpoint driving immune escape and limiting immunotherapeutic efficacy in hepatocellular carcinoma. Journal of Clinical Investigation. 2026;136(11). doi:10.1172/jci200415

BibTeX
@article{Wang2026,
  author = {Wang, Jiong-Liang and Wang, Jun-Cheng and Pan, Yangxun and He, Minrui and Zheng, Zhikai and Zou, Hao and Wu, Tianqing and Zhang, Yuhan and Hu, Zili and Fu, Yizhen and Peng, Wei and Yang, Zhenyun and Xu, Li and Zhang, Yao-Jun and Chen, Min-Shan and Hu, Dandan and Chen, Jinbin and Zhao, Ming and Chen, Dong-Ping and Zhou, Zhong-Guo},
  title = {Tescalcin is a phagocytic checkpoint driving immune escape and limiting immunotherapeutic efficacy in hepatocellular carcinoma},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  volume = {136},
  number = {11},
  doi = {10.1172/jci200415}
}
Kostenlos starten →